濟民製藥(603222.SH)轉讓白水濟民醫院股權7600萬元回購款延期收回
格隆匯12月9日丨濟民製藥(603222.SH)公佈,此前,公司於2018年3月以人民幣1.26億元收購白水濟民醫院60%的股權。由於白水濟民醫院未能完成2018年承諾業績,2019年5月趙選民全額回購公司所持目標公司60%股權,回購對價為人民幣1.39億元,應於2020年12月31日之前付清。截止本公告日,公司已收到趙選民支付的回購款人民幣6261.65萬元及利息人民幣833.33萬元,未支付的剩餘回購價款本金為7600萬元。公司將與公司控股子公司白水濟民醫院原股東趙選民簽署《股權回購協議之補充協議》,同意將剩餘回購款本金7600萬元的期限延期至2021年12月31日之前。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.